Netherlands: Life Sciences, Biotechnology & Nanotechnology

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

Development Of A New EMA Guideline On The Clinical Evaluation Of Ready To Use Radiopharmaceuticals[1]

This post and the paper it links to were prepared at the instruction of Novartis; it reflects the views of the authors.

European Union Healthcare

AP

Arnold & Porter

De EU AI-verordening

Met de inwerkingtreding van Verordening (EU) 2024/1689, beter bekend als de "Artificial...

European Union Technology

NG

Novagraaf Group

National Penalties For Breach Of Medical Device Advertising Rules

We are often asked what are the penalties in Europe for breach of advertising laws for a medical device or in vitro diagnostic (IVD). Even within the EU,

Netherlands Media & IT

TW

Taylor Wessing

New AI Legislation's Reach Extends Into European Healthcare

Compliance with Europe's upcoming regulation laying down harmonised rules on artificial intelligence (AI) is essential for life sciences and healthcare companies relying on the rapidly developing transformative technology.

European Union Technology

OC

Osborne Clarke

Medical Devices In Spotlight Competition Authorities

Netherlands Healthcare

VD

Van Doorne

SPC Waivers Explained By The District Court Of The Hague

TW

Taylor Wessing

EU Assesses Competition Picture Of The Pharma Sector

European Union Healthcare

OC

Osborne Clarke

Le classement des places de marché les plus opaques

European Union IP

NG

Novagraaf Group

Absence de risque de confusion entre des marques pharmaceutiques

European Union IP

NG

Novagraaf Group

Patent Descriptions: T1742/19 And Insufficient Disclosure

European Union IP

NG

Novagraaf Group

Nomination Des Juges De La Juridiction Unifiée Du Brevet (JUB)

European Union IP

NG

Novagraaf Group

New OECD/EUIPO Study Reveals Risk Of Counterfeits To Health, Safety And The Environment

European Union IP

NG

Novagraaf Group

Medical Devices Regulation (MDR) Entered Into Effect

Netherlands Healthcare

LL

Loyens & Loeff

Neurim: A "Rare Wild Animal"?

European Union IP

D

Dentons

VAT Exemption For Intermediation In Share Transactions – Dutch Decree

Netherlands Tax

B

Buren

Anti-ESG Update: Navigating The Backlash On ESG

Netherlands Commercial

LL

Loyens & Loeff

EU Parliament Blocks Trilogue Mandate – Omnibus For CSRD And CSDDD Reforms Is Back In Play

European Union Commercial

LL

Loyens & Loeff

CJEU: The Limitation Period Starts Once The Decision Of The National Competition Authority Becomes Final

Netherlands Anti-trust

LL

Loyens & Loeff

Quarterly Employment Law Insights Q3 2025

Netherlands Employment

AO

A&O Shearman

Amsterdam: The New Pharma Hub In Europe

As of March 2019, Amsterdam will be the proud home of the European Medicines Agency (EMA). It's been confirmed that the EMA will relocate its headquarters from London to Amsterdam due to Brexit.

Netherlands Healthcare

I

Intertrust

European Patent Office Amends Rules For Plant And Animal Patents

The patentability of plant and animal varieties has been a recurring topic of discussion over the years.

European Union IP

DB

De Brauw Blackstone Westbroek N.V.

ECJ: Non-Fertilised Human Ovum Activated By Parthenogenesis Could Be Patentable

The European Court of Justice recently ruled in International Stem Cell Corporation that parthenogenetically activated non-fertilised human ova are not human embryos.

DB

De Brauw Blackstone Westbroek N.V.

Nagoya Protocol Soon To Restrict Use Of Genetic Resources From Other Countries

The ‘Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization’ will enter into force on 12 October 2014.

DB

De Brauw Blackstone Westbroek N.V.

Advocate General: The Use Of Unfertilised Human Ova Is Patentable

DB

De Brauw Blackstone Westbroek N.V.

ECJ Opens Door To SPCs For Safeners In Plant Protection Products

European Union Healthcare

DB

De Brauw Blackstone Westbroek N.V.

Recent European Developments Regarding Supplementary Protection Certificates (SPCs)

European Union IP

DB

De Brauw Blackstone Westbroek N.V.

Court Of Appeal Of The Hague: One SPC Per Patent

Netherlands Healthcare

N

NautaDutilh

US Supreme Court Ruling On Patent Eligibility Of DNA

NO

Nederlandsch Octrooibureau

AstraZeneca - CJEU's Decision Re. Abuse Of Dominant Position (Losec)

Netherlands Healthcare

N

NautaDutilh

Healthcare Policy Meets Patent Law: Preferential Treatment Of Generics While The Originator Has Patent Protection

N

NautaDutilh

Generic Drug May Not Be Included In G-Standard Before Expiration Of Patent

Kv

Kennedy van der Laan

The Importance Of An Explicit Secrecy Clause In Clinical Trials

Netherlands Healthcare

Kv

Kennedy van der Laan

AkzoNobel Signs Agreement To Sell Its Shares In ICI Pakistan

Netherlands Healthcare

DB

De Brauw Blackstone Westbroek N.V.

Healthcare Policy Meets Patent Law: Preferential Treatment Of Generics While The Originator Has Patent Protection

The Court of Appeals of The Hague has recently ruled that healthcare insurance companies, by inviting parties to bid in a tender to become the preferred supplier of a medicinal product which is still under patent protection, do not infringe the originator's patent and do not commit an "unlawful act".

N

NautaDutilh

Generic Drug May Not Be Included In G-Standard Before Expiration Of Patent

The Dutch Supreme Court has ruled in legal proceedings between Glaxo and Pharmachemie, in which the question was whether a generic drug may already be included in the so-called G-Standard before the expiry of the patent of the original drug.

Kv

Kennedy van der Laan

The Importance Of An Explicit Secrecy Clause In Clinical Trials

European Patent Office, Board of Appeal, 7 July 2007, T 0007/07 (Ethinylestradiol and drospirenone for use as a contraceptive/BAYER PHARMA AG)

Netherlands Healthcare

Kv

Kennedy van der Laan

AkzoNobel Signs Agreement To Sell Its Shares In ICI Pakistan

De Brauw Blackstone Westbroek has advised AkzoNobel on reaching an agreement to sell its 75.81 percent shareholding in ICI Pakistan Limited to the Yunus Brothers Group for €124.4 million (subject to a net debt and interest adjustment).

Netherlands Healthcare

DB

De Brauw Blackstone Westbroek N.V.

Nautadutilh And Niaba Publish Report On Market Developments In The Dutch Biotechnology Industry

Netherlands Healthcare

N

NautaDutilh

ECJ Affirms Biotech Directive

Netherlands Healthcare

AS

Arnold & Siedsma

See more

Latest Videos

See more

What Regulatory Challenges Are Facing The Life Sciences Sector? (Video)

WF

William Fry

Webinar Video | Lunch & Learn: Life Sciences : Morceaux Choisis

A

Altius

Webinar Video | Life Sciences Session #2: Vaccine Liability: What If Vaccination Goes Wrong?

A

Altius

Launch Of Our Medical Device Publication (Video)

WF

William Fry

Understanding Sunshine Rules: How New Transparency Regulations In Europe Are Changing Relationships Between Industry And Health Care Professionals (Video)

HL

Hogan Lovells

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More